Good morning, it’s the third of July. This newsletter will be off tomorrow for the holiday and — surprise — all of next week.

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Elizabeth Haase, MD, former chair of the American Psychiatric Association's Committee on Climate Change, shared her advice ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Spravat (esketamine) FastTrack Program by Ketamine Academy Live, step-by-step program to help clinics get certified, operational, and reimbursed for Spravato®-without the usual delays or confusion.

Spravato should be used in conjunction with an oral antidepressant, according to both the FDA and Janssen. The FDA said this is the first time esketamine was approved for any use.

Esketamine has been shown to affect glutamate signaling in a matter of days, while oral antidepressants can take weeks. Spravato isn’t like the nasal spray you use when you have a cold.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to ...